__timestamp | MorphoSys AG | Zoetis Inc. |
---|---|---|
Wednesday, January 1, 2014 | 9689000 | 1643000000 |
Thursday, January 1, 2015 | 10431000 | 1532000000 |
Friday, January 1, 2016 | 9618000 | 1364000000 |
Sunday, January 1, 2017 | 12348000 | 1334000000 |
Monday, January 1, 2018 | 28310241 | 1484000000 |
Tuesday, January 1, 2019 | 59336147 | 1638000000 |
Wednesday, January 1, 2020 | 159145941 | 1726000000 |
Friday, January 1, 2021 | 199800000 | 2001000000 |
Saturday, January 1, 2022 | 90225000 | 2009000000 |
Sunday, January 1, 2023 | 92538000 | 2151000000 |
Monday, January 1, 2024 | 2318000000 |
Unleashing insights
In the ever-evolving landscape of the pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Zoetis Inc. and MorphoSys AG from 2014 to 2023. Over this period, Zoetis Inc. consistently outpaced MorphoSys AG in SG&A spending, reflecting its expansive operational scale. In 2023, Zoetis Inc.'s SG&A expenses reached approximately $2.15 billion, marking a 31% increase from 2014. In contrast, MorphoSys AG's expenses peaked in 2021 at nearly $200 million, a significant rise from its 2014 figures. This disparity highlights Zoetis Inc.'s robust market presence and strategic investments in growth, while MorphoSys AG's more modest spending underscores its focused approach. As the industry continues to grow, these financial strategies will play a pivotal role in shaping the future trajectories of these companies.
Selling, General, and Administrative Costs: Eli Lilly and Company vs MorphoSys AG
Cost Management Insights: SG&A Expenses for AstraZeneca PLC and Zoetis Inc.
Zoetis Inc. and Genmab A/S: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Zoetis Inc. vs Viatris Inc.
Zoetis Inc. vs Dr. Reddy's Laboratories Limited: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Zoetis Inc. or Sarepta Therapeutics, Inc.
Comparing SG&A Expenses: Zoetis Inc. vs Rhythm Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Agios Pharmaceuticals, Inc.
Comparing SG&A Expenses: Zoetis Inc. vs MannKind Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of TG Therapeutics, Inc. and MorphoSys AG
Who Optimizes SG&A Costs Better? MorphoSys AG or Wave Life Sciences Ltd.
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.